Comment on the TRIBE2 study on first and secondline treatment for metastatic colorectal cancer

Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer

07:56 EDT 25 Oct 2018 | ecancermedicalscience

Dr Filippo Pietrantonio speaks to ecancer at the ESMO 2018 congress in Munich about the TRIBE-2 study for patients with metastatic colorectal cancer. Dr Pietrantonio believes the TRIBE-2 trial is very important as it is setting a new standard in first...

More From BioPortfolio on "Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer"